Stay updated with breaking news from Nasdaq Fdmt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) is one of 264 public companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare 4D Molecular Therapeutics to similar businesses based on the strength of its risk, profitability, earnings, valuation, dividends, institutional ownership and analyst recommendations. Institutional & […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) and Axcella Health (NASDAQ:AXLA – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Institutional and Insider Ownership 76.6% of 4D Molecular […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses […]
4D Molecular Therapeutics (NASDAQ:FDMT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, “4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated […]